Cargando…
Antidepressant efficacy and side effect burden: an updated guide for clinicians
Antidepressant treatment has been evolving and changing since the 1950s following the discovery of the classic antidepressant treatments including tricyclic antidepressants and monoamine oxidase inhibitors. The heterogeneity of the disorder became apparent in the beginning when individuals remained...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255467/ https://www.ncbi.nlm.nih.gov/pubmed/32523610 http://dx.doi.org/10.7573/dic.2020-2-2 |
_version_ | 1783539737177358336 |
---|---|
author | Kutzer, Tatum Dick, Michelle Scudamore, Trevor Wiener, Mark Schwartz, Thomas |
author_facet | Kutzer, Tatum Dick, Michelle Scudamore, Trevor Wiener, Mark Schwartz, Thomas |
author_sort | Kutzer, Tatum |
collection | PubMed |
description | Antidepressant treatment has been evolving and changing since the 1950s following the discovery of the classic antidepressant treatments including tricyclic antidepressants and monoamine oxidase inhibitors. The heterogeneity of the disorder became apparent in the beginning when individuals remained symptomatic despite medication compliance. This spurred further research in order to understand the neurobiology underlying the disorder. Subsequently, newer medications were designed to target specific neurotransmitters and areas of the brain involved in symptom development and maintenance. Our original review article looked at both classic and modern antidepressant medications used in the treatment of major depressive disorder. This manuscript is an update to the original review and serves to provide clinicians with information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment efforts. |
format | Online Article Text |
id | pubmed-7255467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioExcel Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-72554672020-06-09 Antidepressant efficacy and side effect burden: an updated guide for clinicians Kutzer, Tatum Dick, Michelle Scudamore, Trevor Wiener, Mark Schwartz, Thomas Drugs Context Review Antidepressant treatment has been evolving and changing since the 1950s following the discovery of the classic antidepressant treatments including tricyclic antidepressants and monoamine oxidase inhibitors. The heterogeneity of the disorder became apparent in the beginning when individuals remained symptomatic despite medication compliance. This spurred further research in order to understand the neurobiology underlying the disorder. Subsequently, newer medications were designed to target specific neurotransmitters and areas of the brain involved in symptom development and maintenance. Our original review article looked at both classic and modern antidepressant medications used in the treatment of major depressive disorder. This manuscript is an update to the original review and serves to provide clinicians with information about novel antidepressant medications, augmentation strategies with atypical antipsychotics, over-the-counter medications, as well as nonpharmaceutical treatments that should be considered when treating each individual patient who remains symptomatic despite treatment efforts. BioExcel Publishing Ltd 2020-05-26 /pmc/articles/PMC7255467/ /pubmed/32523610 http://dx.doi.org/10.7573/dic.2020-2-2 Text en Copyright © 2020 Kutzer T, Dick M, Scudamore T, Wiener M, Schwartz T. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission. |
spellingShingle | Review Kutzer, Tatum Dick, Michelle Scudamore, Trevor Wiener, Mark Schwartz, Thomas Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title | Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_full | Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_fullStr | Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_full_unstemmed | Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_short | Antidepressant efficacy and side effect burden: an updated guide for clinicians |
title_sort | antidepressant efficacy and side effect burden: an updated guide for clinicians |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255467/ https://www.ncbi.nlm.nih.gov/pubmed/32523610 http://dx.doi.org/10.7573/dic.2020-2-2 |
work_keys_str_mv | AT kutzertatum antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT dickmichelle antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT scudamoretrevor antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT wienermark antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians AT schwartzthomas antidepressantefficacyandsideeffectburdenanupdatedguideforclinicians |